ValuEngine upgraded shares of Inogen (NASDAQ:INGN) from a hold rating to a buy rating in a research report report published on Friday.
A number of other equities analysts have also issued reports on INGN. BidaskClub lowered shares of Inogen from a hold rating to a sell rating in a research report on Saturday, January 6th. Zacks Investment Research raised shares of Inogen from a hold rating to a buy rating and set a $128.00 price target for the company in a report on Tuesday, January 9th. Piper Jaffray raised shares of Inogen from a neutral rating to an overweight rating in a report on Tuesday, February 20th. Finally, Needham & Company LLC upped their price target on shares of Inogen from $125.00 to $150.00 and gave the company a strong-buy rating in a report on Wednesday, February 28th. Three research analysts have rated the stock with a hold rating, five have given a buy rating and one has issued a strong buy rating to the company. The stock currently has an average rating of Buy and a consensus price target of $107.29.
Shares of INGN opened at $128.00 on Friday. The stock has a market capitalization of $2,766.28, a P/E ratio of 97.71, a P/E/G ratio of 3.63 and a beta of 1.03. Inogen has a 52-week low of $74.06 and a 52-week high of $134.97.
Inogen (NASDAQ:INGN) last announced its earnings results on Tuesday, February 27th. The medical technology company reported $0.31 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $0.21 by $0.10. The firm had revenue of $63.79 million during the quarter, compared to analyst estimates of $62.01 million. Inogen had a net margin of 8.42% and a return on equity of 13.47%. equities analysts forecast that Inogen will post 1.6 earnings per share for the current fiscal year.
In other Inogen news, EVP Alison Bauerlein sold 27,630 shares of the company’s stock in a transaction dated Monday, February 12th. The shares were sold at an average price of $116.46, for a total value of $3,217,789.80. Following the completion of the sale, the executive vice president now directly owns 11,718 shares of the company’s stock, valued at approximately $1,364,678.28. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, insider Scott Wilkinson sold 30,651 shares of the company’s stock in a transaction dated Tuesday, January 16th. The shares were sold at an average price of $115.75, for a total transaction of $3,547,853.25. Following the completion of the sale, the insider now directly owns 38,107 shares of the company’s stock, valued at $4,410,885.25. The disclosure for this sale can be found here. Insiders sold a total of 158,369 shares of company stock valued at $18,919,065 over the last three months. 5.31% of the stock is owned by corporate insiders.
A number of hedge funds and other institutional investors have recently modified their holdings of INGN. Nationwide Fund Advisors lifted its stake in Inogen by 2.5% during the third quarter. Nationwide Fund Advisors now owns 80,007 shares of the medical technology company’s stock valued at $7,609,000 after buying an additional 1,950 shares in the last quarter. Sei Investments Co. lifted its stake in Inogen by 61.7% during the third quarter. Sei Investments Co. now owns 2,597 shares of the medical technology company’s stock valued at $247,000 after buying an additional 991 shares in the last quarter. Rhumbline Advisers lifted its stake in Inogen by 4.3% during the third quarter. Rhumbline Advisers now owns 33,512 shares of the medical technology company’s stock valued at $3,187,000 after buying an additional 1,390 shares in the last quarter. SG Americas Securities LLC purchased a new stake in Inogen during the third quarter valued at about $213,000. Finally, Ameriprise Financial Inc. lifted its stake in Inogen by 6.0% during the third quarter. Ameriprise Financial Inc. now owns 187,068 shares of the medical technology company’s stock valued at $17,781,000 after buying an additional 10,669 shares in the last quarter. 99.49% of the stock is owned by institutional investors.
TRADEMARK VIOLATION WARNING: This news story was posted by Dispatch Tribunal and is the sole property of of Dispatch Tribunal. If you are viewing this news story on another site, it was copied illegally and republished in violation of US and international trademark & copyright law. The original version of this news story can be viewed at https://www.dispatchtribunal.com/2018/04/07/inogen-ingn-upgraded-at-valuengine.html.
Inogen, Inc, a medical technology company, primarily develops, manufactures, and markets portable oxygen concentrators for patients, physicians and other clinicians, and third-party payors in the United States and internationally. The company's oxygen concentrators are used to deliver supplemental long-term oxygen therapy to patients suffering from chronic respiratory conditions.
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Inogen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Inogen and related companies with MarketBeat.com's FREE daily email newsletter.